A detailed history of Dimensional Fund Advisors LP transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 51,284 shares of ATNM stock, worth $75,387. This represents 0.0% of its overall portfolio holdings.

Number of Shares
51,284
Previous 111,869 54.16%
Holding current value
$75,387
Previous $827,000 88.39%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$1.72 - $8.0 $104,206 - $484,680
-60,585 Reduced 54.16%
51,284 $96,000
Q2 2024

Aug 09, 2024

SELL
$6.56 - $9.89 $213,829 - $322,374
-32,596 Reduced 22.56%
111,869 $827,000
Q1 2024

May 10, 2024

SELL
$5.0 - $9.2 $14,860 - $27,342
-2,972 Reduced 2.02%
144,465 $1.13 Million
Q4 2023

Feb 07, 2024

SELL
$4.02 - $6.08 $61,634 - $93,218
-15,332 Reduced 9.42%
147,437 $748,000
Q3 2023

Nov 09, 2023

SELL
$5.91 - $7.37 $102,692 - $128,061
-17,376 Reduced 9.65%
162,769 $963,000
Q2 2023

Aug 09, 2023

SELL
$7.15 - $9.39 $2,523 - $3,314
-353 Reduced 0.2%
180,145 $1.34 Million
Q1 2023

May 12, 2023

BUY
$8.51 - $14.26 $141,078 - $236,402
16,578 Added 10.11%
180,498 $1.71 Million
Q4 2022

Feb 09, 2023

BUY
$7.05 - $14.41 $327,148 - $668,681
46,404 Added 39.49%
163,920 $1.75 Million
Q3 2022

Nov 10, 2022

BUY
$4.81 - $8.48 $433,919 - $764,997
90,212 Added 330.4%
117,516 $867,000
Q1 2022

May 13, 2022

BUY
$4.57 - $6.4 $5,461 - $7,648
1,195 Added 4.58%
27,304 $140,000
Q4 2021

Feb 09, 2022

BUY
$6.01 - $8.8 $90,330 - $132,264
15,030 Added 135.66%
26,109 $157,000
Q3 2021

Nov 12, 2021

BUY
$5.76 - $9.67 $63,815 - $107,133
11,079 New
11,079 $98,000

Others Institutions Holding ATNM

About Actinium Pharmaceuticals, Inc.


  • Ticker ATNM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,184,700
  • Market Cap $37M
  • Description
  • Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...
More about ATNM
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.